Trial Profile
An open label, randomized phase III trial comparing 2.5 year duration of letrozole (Femara) treatment with 5 year duration in patients previously treated for endocrine sensitive early breast cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Feb 2022
Price :
$35
*
At a glance
- Drugs Letrozole (Primary)
- Indications Adenocarcinoma; Early breast cancer
- Focus Therapeutic Use
- Acronyms IDEAL
- 08 Jun 2021 Results (n=908) presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Results of a prospective-retrospective blinded analysis from extended ovaerall and Ph+ cohort based on breast cancer index predictions presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 23 Aug 2017 Results published online in the Journal of the National Cancer Institute (online publication date: 23 August 2017; print publication date: January 2018)